Clik here to view.
Nuvo Research to release Phase 2 WF10 data in Q1
Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a...
View ArticleClik here to view.
Nuvo Research receives third U.S. patent
The U.S. Patent and Trademark Office has granted Nuvo Research (TSX:NRI) a patent related to the use of formulations that include chlorite ions, such as its WF10, to treat or inhibit allergy-like...
View ArticleClik here to view.
Nuvo cites placebo effect in WF10 trial
Nuvo Research (TSX:NRI) cited a placebo effect for its WF10 failing to achieve statistical significance in a Phase 2 trial in Germany for the treatment of refractory allergic rhinitis. Each of the...
View ArticleClik here to view.
Nuvo Research outlines strategic plans
Nuvo Research (TSX:NRI) has examined strategic alternatives with a view to increasing shareholder value by obtaining better recognition of its assets. After examining alternative structures and...
View ArticleClik here to view.
Nuvo outlines new WF10 Phase 2 trial
Nuvo Research (TSX:NRI) has provided additional details of the 2015 WF10 Phase 2 trial to assess WF10 for the treatment of allergic rhinitis. The 2015 WF10 trial will be a randomized, double-blind,...
View ArticleClik here to view.
Nuvo gets Health Canada approval for Phase 2 trial
Nuvo Research (TSX:NRI) has received Health Canada approval to conduct a new Phase 2 clinical trial to assess WF10 for the treatment of allergic rhinitis. The 2015 WF10 Trial will begin this month. It...
View Article
